Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
The International Working Group presents what they consider to be the current limitations of biomarkers, and on the basis of this evidence, recommend that diagnosis be restricted to people who have positive biomarkers together with specific Alzheimer's disease phenotypes.
Source:
The Lancet Neurology
SPS commentary:
The group also recommend that biomarker-positive cognitively unimpaired individuals should be considered only at-risk for progression to Alzheimer's disease. A related commentary notes that ultimately, the question of how best to diagnose Alzheimer's disease will revolve around therapy: at what point, and in whom treatment should be started? The relative importance of clinical examination and biomarkers will depend on the answer.